Company: HCTI
Filing Date: 2025-03-05
Form Type: PRE 14C
Source: 0001213900-25-020571
Chunk: 16

Company: Healthcare Triangle, Inc.
Filing Date: 2025-03-05
Form: PRE 14C
Chunk 16
---
 and
Adjustment Share Amount for such exercised Warrants shall be calculated as stated in the previous paragraph.

The Purchase Warrants
also contain anti-dilution protection (subject to the floor price of $0.084) against Dilutive Issuances (as defined in the Purchase Warrants),
whereby the exercise price and the number of shares of Common Stock underlying the Purchase Warrants is subject to reset in the same
manner as described above.

The exercise price (subject
to the floor price of $0.084) and number of shares of Common Stock underlying the Purchase Warrants will also reset if there occurs any
share split, reverse share split, share dividend, share combination recapitalization or other similar transaction involving the Company’s
Common Stock (each, a “Share Combination Event”) and the lowest Weighted Average Price of the Common Stock during
the period commencing on the trading day immediately following the applicable Share Combination Event and ending on the fifth (5th) trading
day immediately following the applicable Share Combination Event Date is less than the Exercise Price then in effect in the same manner
described above.

<div align='center'>9</div>

At any time after Stockholder
Approval has occurred, the Series B Warrants may also be exercised on an alternative cashless basis pursuant to which the number of shares
issuable upon such alternative cashless exercise of this Warrant shall equal the product of (i) the aggregate number of shares of Common
Stock that would be issuable upon exercise of the Series B Warrants if such exercise were by means of a cash exercise rather than a cashless
exercise, multiplied by (ii) 3.0.

On February 24, 2025,
the Majority Stockholders approved by written consent the all of the terms of the Purchase Warrants, including, but not limited to the
exercise of the Purchasea Warrants and the resulting issuance of Common Stock pursuant to the terms of the Purchase Warrants as described
above.

Nasdaq Stockholder Approval Requirement; Reasons for the Warrant Exercise Approval

Nasdaq Listing Rule 5635(d) requires stockholder
approval in connection with a transaction, other than a public offering, involving the sale or issuance by the issuer of common stock
(or securities convertible into or exchangeable for common stock) equal to 20% or more of the common stock or 20% or more of the voting
power of such company outstanding before the issuance for a price that is less than the lower of: